

South Carolina
Department of Health and Human Services
Post Office Box 8206
Columbia, South Carolina 29202-8206

Pharmacy and Therapeutics (P&T) Committee Meeting
March 28, 2024
MINUTES

1. Call to Order

A meeting of the P&T Committee convened at 4:00 p.m. on Thursday, March 28, 2024.

2. Welcome

Edward Behling, MD, called the meeting to order and welcomed members, guests, and staff members.

Dr. Behling opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

3. Committee Members Present:

Edward Behling, MD
Kimberly Rudd, MD
Cheryl Hartvigsen, RPh

Kelly Barth, DO
Patricia Witherspoon, MD
Divya Ahuja, MD

Philip Mubarak, MD
Thomas Phillips, RPh
Duncan Norton, MD

SC DHHS Staff:

Cheryl Anderson, RPh
Kevin Wessinger, MD
Kim Bristow, RPh
Brandie Crider, CPhT
Tawanna Ziegler, CPhT
Ashley Sirianni, DNP

Magellan Medicaid Admin:

Lisa Correll, PharmD
Blake Cook, RPh
Lori Ash

4. Discussion Topics

A. Committee Meeting Minutes, Wednesday, November 1, 2023

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

B. Public Comment

Company	Speaker	Drug/Class
Braeburn	John Landis, PharmD	Brixadi® / Medication Assisted Treatment

C. Drug Classes for Review

Classes for Re-review

- Medication Assisted Treatment (Medications for Opioid Use Disorder)
- Bronchodilators, β Agonist Short Acting – Inhaled
- Bronchodilators, β Agonist Long Acting – Inhaled
- Glucocorticoids, Inhaled

The chart below represents the recommendations from the State:

MEDICATION ASSISTED TREATMENT	
Preferred	Non-Preferred
Brixadi® inj ¹	buprenorphine/naloxone SL film
buprenorphine SL tabs ¹	Zubsolv® tabs
buprenorphine/naloxone SL tab	
Sublocade® inj	
Suboxone® SL film	
Vivitrol® inj	
BRONCHODILATORS, β AGONIST SHORT ACTING - INHALED	
Preferred	Non-Preferred
albuterol HFA (generic and AG Proventil) ¹	albuterol HFA (ProAir) ²
ProAir® HFA (<i>discontinued</i>)	albuterol HFA (Ventolin)
ProAir Respiclick® ¹	levalbuterol HFA
Proventil® HFA (<i>discontinued</i>)	ProAir® Digihaler
Ventolin® HFA	Xopenex® HFA inhalation soln ²
BRONCHODILATORS, β AGONIST LONG ACTING - INHALED	
Preferred	Non-Preferred
arformoterol ¹	Brovana®
Serevent® Diskus®	formoterol
	Perforomist®
	Striverdi® Respimat®
GLUCOCORTICOIDS, INHALED	
Preferred	Non-Preferred
Alvesco® ¹	Armonair® Digihaler®
Arnuity® Ellipta® ¹	fluticasone Diskus ²
Asmanex® Twisthaler®	Pulmicort Flexhaler ²
Asmanex® HFA ¹	Pulmicort Respules®

GLUCOCORTICIDS, INHALED (continued)	
Preferred	Non-Preferred
budesonide Respules	
Flovent HFA®	
fluticasone HFA ¹	
Flovent® Diskus®	
Qvar® Redihaler® ¹	

¹ Added as “Preferred”

² Moved to “Non-Preferred”

5. Old Business

None

6. New Business

Dr. Wessinger, Chief Medical Officer, shared the agency’s plan to transition to Single PDL and will expand coverage of Continuous Glucose Monitors (CGMs) effective July 1, 2024. Cheryl Anderson RPh, SC Pharmacy Director, updated the committee on 4 membership openings, 2 physicians and 2 pharmacists. Currently, 3 candidates are under consideration. The new P&T pharmacist will join the Prime team early May. Pharma Days/Meetings will begin in July and run through mid-November. Meetings will be held on Friday mornings, be 50 minutes in length and randomized as in years past. Director Anderson also informed the P&T Committee of the May P&T date being moved to June 12th at 3pm.

Lisa Correll presented new drugs to market. Pharma meetings are offered for 1 entity per year and remain virtual in 2024.

7. Actions of the P&T Committee

Classes for Re-review

- Medication Assisted Treatment (Medications for Opioid Use Disorder)
- Bronchodilators, β Agonist Short Acting – Inhaled
- Bronchodilators, βAgonist Long Acting – Inhaled
- Glucocorticoids, Inhaled

The above referenced classes for re-review and the products reflected in 4.c were unanimously approved by the P&T committee.

8. Closing Comments

The next meeting will be held Wednesday, June 12, 2024 at 3pm.

9. Adjournment

The meeting adjourned at 5:14 p.m.